In the Boardroom
Refine search
Biotechnology
US clinical-stage biotech Neurogene today announced the appointment of Christy Shafer as chief commercial officer and the appointment of Christine Mikail to its board of directors. 20 April 2026
Pharmaceutical
Achieve Life Sciences, a late-stage specialty pharma company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, has appointed Andrew Goldberg as its new chief executive and member of the board. 17 April 2026
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
French immunotherapy company OSE Immunotherapeutics provided a senior management update. 15 April 2026
Biotechnology
German drug discovery company Evotec today announced the appointment of Dr Ingrid Müller as chief operating officer (COO). 15 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Pharmaceutical
Lotte Bjerre Knudsen, chief scientific advisor to the chief scientific officer, vice president of innovation and data experimentation advancement (IDEA) at Danish pharma major Novo Nordisk, is to leave the company after 36 years. 13 April 2026
Biotechnology
Canada-based biotech Zymeworks today announced the full-time appointments of Dr Adam Schayowitz and Scott Platshon as of April 9, 2026, from their previously interim roles. 9 April 2026
Biotechnology
Swiss biotech Idorsia has announced the appointment of Dr Amer Joseph as executive vice president, chief medical officer (CMO) and head of global clinical development, effective May 1, 2026. He succeeds Dr Alberto Gimona, who is retiring. 9 April 2026
Biotechnology
France’s Orano Group today announced that Frederic Desdouits has been appointed chief executive (CEO) of its subsidiary Orano Med, a biotechnology company pioneering the development of targeted alpha therapies in oncology. 8 April 2026
Pharmaceutical
Norway based immune-oncology medicines developer Lytix Biopharma today announced the appointment of Renée Christine Amundsen as chief operating officer (COO), effective immediately. 7 April 2026
Pharmaceutical
US cardiorenal-focussed drugmaker Ardelyx announced the appointment of Rajani Dinavahi as Chief Medical Officer (CMO). 4 April 2026
Pharmaceutical
US biotechnology company PranaX has appointed Richard LeConey as chief medical officer, as it looks to strengthen clinical oversight of its exosome-based portfolio in a fast-evolving but loosely regulated market. 2 April 2026
Biotechnology
US biotech Nanoscope Therapeutics has appointed Paul Hallen as chief operating officer, adding commercial and operational firepower as it prepares for a potential first product launch. 2 April 2026
Biotechnology
US biotech Protillion Biosciences has appointed Robert Hollingsworth as chief scientific officer, bringing in a seasoned R&D leader as the company looks to shift from platform development toward pipeline execution. 1 April 2026
Biotechnology
German drug discovery company Evotec today announced the appointment of Dr Ashiq Khan as executive vice president, global head, chief commercial officer. 1 April 2026
Biotechnology
Austrian biotech Proxygen, which is pioneering the discovery of molecular glue degraders and next-generation proximity-based therapeutics, today announced the appointment of Chiara Conti, as chief scientific officer (CSO). 31 March 2026
Biotechnology
San Diego, USA-based late-stage biotech ADARx Pharmaceuticals announced the appointment of Ryan Fisk as chief financial officer and chief business officer. In this role, he will be responsible for leading finance, strategy, corporate development and investor relations for the company. 28 March 2026
Biotechnology
Averna Therapeutics, a US biotech developing novel genomic medicines based on gene insertion technology, has announced the appointments of Robert Mabry as chief scientific officer (CSO) and Richard Morris as chief financial officer (CFO). 27 March 2026
Biotechnology
US biotech Outlook Therapeutics, which is specializing in the development and commercialization of Lytenava (bevacizumab-vikg), has appointed Greg DiPasquale as its chief commercial officer (CCO). 9 October 2026
Pharmaceutical
UK-based Pharmanovia has appointed Béchir Ben Hadj Yahia as global head of medical affairs, as it expands its presence in specialty oncology. 7 October 2026
Biotechnology
French hearing loss specialist Sensorion today announced the appointment of Louis “Lou” Arcudi III as chief financial officer (CFO), effective October 7, 2026, replacing Laurene Danon. 7 October 2026
Biotechnology
Clinical-stage biotech ProMIS Neurosciences, which is developing neurodegenerative diseases drugs, including Alzheimer’s disease, today announced the appointment of Ivana Rubino, as chief commercial officer (CCO), effective October 5, 2026. 6 October 2026
Biotechnology
UK privately-held biotech RQ Bio has announced the appointment of Gavin Koh as chief medical officer (CMO). 6 October 2026
Biotechnology
Swedish immuno-oncology firm Alligator Bioscience has announced the appointment of Johan Giléus as Alligator’s new chief executive (CEO), effective 1 January 2027. 5 October 2026
Pharmaceutical
German pharma major Bayer has appointed Christoph Koenen as chief medical officer, a newly reinforced role he will hold alongside his current position as head of clinical development and operations for the company's Pharmaceuticals Division. 1 October 2026
Biotechnology
Swiss clinical-stage biotech Numab Therapeutics, which is advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, today announced the appointment of Dr Rajesh Chopra as chief scientific officer (CSO). 1 October 2026
Biotechnology
Cambridge, USA-based mRNA vaccines company Moderna today announced the addition of a chief operating officer (COO) role to support the increasing scale and diversification of the company. 30 September 2026
Biotechnology
German biotech T-CURX GmbH, which is developing non-viral CAR-T therapies, today announced the appointment of Florian Schmid as chief financial officer (CFO). 30 September 2026
Biotechnology
Xilio Therapeutics, a US biotech developing masked immuno-oncology therapies, has appointed Yariv Houvras as chief medical officer, as the company advances XTX501, a bispecific PD-1/masked IL-2 candidate, through the clinic alongside its next generation of multi-specific, masked T-cell engagers. 28 September 2026
Biotechnology
California, USA-based Circle Pharma today announced the promotion of Marie Evangelista to chief scientific officer and the appointment of Mary Ellen Sillivos as senior vice president and head of human resources. 28 September 2026
Biotechnology
US clinical-stage biotech company Tortugas Neuroscience has announced the appointment of Ramzi Benamar as chief financial officer (CFO). 25 September 2026
Generics
UK-based generics and injectables major Hikma Pharmaceuticals has announced the appointment of Rebecca Hall as its new chief financial officer and executive director. Ms Hall is expected to officially join the leadership team in the first quarter of 2027, bringing extensive global pharmaceutical experience to the role. 24 September 2026
Biotechnology
UK biotech Engitix, which is pioneering extracellular matrix (ECM)-driven drug discovery, today announced the appointment of Dr Sonia Quaratino in the newly created role of executive vice president, chief medical officer (CMO). 23 September 2026
Biotechnology
Anavo Therapeutics, the Netherlands-based biotech developing phosphatase-targeted drugs, has appointed Vincent Brichard as chairman of its board of directors, as the company advances three potentially first-in-class pipeline programs in autoimmune, metabolic and oncology disease. 22 September 2026
Biotechnology
French genetic medicines company Cyllene Therapeutics has appointed Dr Marc Grasso as executive vice president and chief financial officer (CFO). 21 September 2026
Biotechnology
Danish vaccine maker Bavarian Nordic has named Tarja Stenvall as president and chief executive with effect from October 15, closing a search that opened in March when Paul Chaplin said he would step down after 12 years in the job and nearly three decades at the company. She joins from French pharma major Sanofi. 18 September 2026
Biotechnology
US-centered cell therapy company Legend Biotech has appointed Ingrid Zhang as chief executive officer (CEO) following a board-led search process. 17 September 2026
Biotechnology
Swiss-US biotech company GlycoEra has appointed Andrea Matthews as chief business officer, recruiting a dealmaker from one of the past year's larger rare disease takeouts as the privately held protein degrader specialist prepares to put its lead autoimmune candidate in front of partners and investors. 17 September 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze